| HUMAN-TRIAL | evidence | Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus | Semaglutide | n = 480 | — |
| HUMAN-TRIAL | evidence | Glycemic and Weight Loss Effects of GLP-1R Agonist Therapy in Subjects With Spinal Cord Injury and Type 2 Diabetes | Ozempic | human-observational · n = 50 | — |
| HUMAN-TRIAL | evidence | Pharmacoscintigraphic Investigation of NN9924 in Healthy Male Subjects | Semaglutide | Glycemic control · human-rct · n = 27 | — |
| HUMAN-TRIAL | evidence | Investigating the Pharmacokinetics, Safety and Tolerability After a Single Subcutaneous Injection of Semaglutide in Subjects With Mild, Moderate or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function | Semaglutide | Glycemic control · human-rct · n = 44 | — |
| HUMAN-TRIAL | evidence | Research Study to Compare Three Doses of Semaglutide Tablets Taken Once Daily in People With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 1606 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Spain, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 230 | — |
| HUMAN-TRIAL | evidence | A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight | Semaglutide | human-rct · n = 512 | — |
| HUMAN-TRIAL | evidence | Dose-response, Safety and Efficacy of Oral Semaglutide Versus Placebo and Versus Liraglutide, All as Monotherapy in Japanese Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 243 | — |
| HUMAN-TRIAL | evidence | A Study of Enlicitide Decanoate (MK-0616) and Semaglutide in Healthy Adult Participants (MK-0616-023) | Rybelsus | n = 38 | — |
| HUMAN-TRIAL | evidence | Incretin Microdosing for Cardiometabolic Health in People With HIV | Semaglutide | human-rct · n = 30 | — |
| HUMAN-TRIAL | evidence | A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus) | Semaglutide | Cognition & memory · human-rct · n = 1840 | — |
| HUMAN-TRIAL | evidence | Cessation or Reduction of Alcohol Consumption in Veterans: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of a GLP-1 Receptor Agonist Semaglutide in U.S. Veterans With Alcohol Use Disorder | Semaglutide | Addiction & substance use · human-rct · n = 622 | — |
| HUMAN-TRIAL | evidence | Semaglutide Treatment in Type 1 Diabetes | Semaglutide | human-rct · n = 122 | — |
| HUMAN-TRIAL | evidence | Epicardial Cardiac Fat-CT (EPIC-CT) | Rybelsus | human-rct · n = 136 | — |
| HUMAN-TRIAL | evidence | Treatment of GLP-1 for Diabetic Bariatric Patients | Semaglutide | Glycemic control · human-rct · n = 3 | — |
| HUMAN-TRIAL | evidence | Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes | Semaglutide | Glycemic control · human-rct · n = 96 | — |
| HUMAN-TRIAL | evidence | GLP-1 RA for Stage 1 Type 1 Diabetes | Semaglutide | Glycemic control · human-rct · n = 15 | — |
| HUMAN-TRIAL | evidence | The Effect of Semaglutide on Bone Health | Semaglutide | Bone & joint health · human-rct · n = 150 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin in Subjects With Type 2 Diabetes (SUSTAIN - CHINA MRCT) | Semaglutide | Glycemic control · human-rct · n = 868 | — |
| HUMAN-TRIAL | evidence | Comparison of Oral Semaglutide w/ Placebo- Treatment for Latino Adults w/T2 Diabetes Receiving Enhanced Lifestyle Care | Semaglutide | Glycemic control · human-rct · n = 12 | — |
| HUMAN-TRIAL | evidence | Novel Therapeutics and Endothelial Dysfunction in T1DM Patients | Ozempic | Glycemic control · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 158 | — |
| HUMAN-TRIAL | evidence | Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR) | Ozempic | Glycemic control · human-observational · n = 34238 | — |
| HUMAN-TRIAL | evidence | 16-week Flexible vs. 8-week Semaglutide Titration | Ozempic | Glycemic control · human-rct · n = 100 | — |
| HUMAN-TRIAL | evidence | Oral Semaglutide in Patients With Alzheimer's Disease | Rybelsus | Cognition & memory · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide | NN9535 | Glycemic control · human-rct · n = 415 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IV | Semaglutide | Glycemic control · human-rct · n = 90 | — |
| HUMAN-TRIAL | evidence | Semaglutide and Intestinal Iron Absorption | Semaglutide | Glycemic control · n = 51 | — |
| HUMAN-TRIAL | evidence | Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes | Wegovy | Weight & fat loss · human-observational · n = 125000 | — |
| HUMAN-TRIAL | evidence | Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2) | Semaglutide | Glycemic control · human-rct · n = 956 | — |
| HUMAN-TRIAL | evidence | Free Fatty Acid Effects In Type 2 Diabetes | Semaglutide | human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How 50 mg Semaglutide Daily Affects Food Intake and Emptying of the Stomach in People With Obesity | Semaglutide | Weight & fat loss · human-rct · n = 60 | — |
| HUMAN-TRIAL | evidence | Semaglutide GLP1 Agonists With Degludec Basal-bolus Insulin in Early Type 1 Diabetes to Basal-bolus | Semaglutide | Glycemic control · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | Efficacy and Safety of Semaglutide Once-weekly Versus Sitagliptin Once-daily as add-on to Metformin and/or TZD in Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 1231 | — |
| HUMAN-TRIAL | evidence | Effects of Semaglutide in HIV-Associated Lipohypertrophy | Ozempic | Weight & fat loss · human-rct · n = 108 | — |
| HUMAN-TRIAL | evidence | A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE) | Semaglutide | human-rct · n = 573 | — |
| HUMAN-TRIAL | evidence | A Research Study of How Oral Semaglutide Tablets Work in Healthy People Who Are Chinese | Semaglutide | Glycemic control · human-rct · n = 32 | — |
| HUMAN-TRIAL | evidence | Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL) | Semaglutide | human-observational · n = 25664 | — |
| HUMAN-TRIAL | evidence | Safety and Efficacy of Oral Semaglutide Versus Dulaglutide Both in Combination With One OAD (Oral Antidiabetic Drug) in Japanese Subjects With Type 2 Diabetes | Semaglutide | Glycemic control · human-rct · n = 458 | — |
| HUMAN-TRIAL | evidence | The Effect of Semaglutide on Cardiovascular Markers and Liver Function | Semaglutide | Glycemic control · human-observational · n = 50 | — |
| HUMAN-TRIAL | evidence | Brain Plasticity and GLP-1 Receptor Agonist Treatment for Obesity | Semaglutide | Weight & fat loss · human-rct · n = 120 | — |
| HUMAN-TRIAL | evidence | A Multicentre, Prospective, Single-arm, Non-interventional Regulatory Post-marketing Surveillance (rPMS) Study to Investigate the Safety and Effectiveness of Wegovy® (Semaglutide) in Patients With Obesity and Patients With Overweight in Routine Clinical Practice in Korea | Wegovy | Weight & fat loss · human-observational · n = 840 | — |
| HUMAN-TRIAL | evidence | Special Use - Results Surveillance on Long-term Use With Wegovy® | Wegovy | Weight & fat loss · human-observational · n = 1071 | — |
| HUMAN-TRIAL | evidence | Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy | Semaglutide | Weight & fat loss · human-rct · n = 15 | — |
| HUMAN-TRIAL | evidence | DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy | Semaglutide | Glycemic control · human-observational · n = 291 | — |
| HUMAN-TRIAL | evidence | Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD) | Semaglutide | Glycemic control · human-rct · n = 64 | — |
| HUMAN-TRIAL | evidence | Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects. | Ozempic | Glycemic control · human-rct · n = 68 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in Switzerland, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 194 | — |
| HUMAN-TRIAL | evidence | A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in Italy, as Part of Local Clinical Practice | Semaglutide | Glycemic control · human-observational · n = 581 | — |
| HUMAN-TRIAL | evidence | Testing the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss. | Ozempic | Weight & fat loss · human-rct · n = 164 | — |